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Abstract 
Thirty patients with various ocular surface inflammations were enrolled in a double-masked study 
comparing ketorolac tromethamine 0.5% (Acular) and diclofenac sodium 0.1% (Voltaren Ophthalmic). At 
the initial visit, baseline measurements of various inflammatory signs were taken. The patients were 
instructed to use Acular in one eye and Voltaren Ophthalmic in the other eye four times a day for a period 
of seven days. After this seven day treatment period, the patients completed a questionnaire and were 
evaluated for signs of inflammation. At this time, the drops were reversed for each eye. Once again the 
patients were instructed to use the drops four times daily for seven days. After this second week of 
treatment the patients were reevaluated for signs and symptoms of inflammation. Quantification of signs 
and symptoms occurred at the one week and two week evaluations. After two weeks the Acular-treated 
eyes showed significant decreases in conjunctival injection (p = 0.0192), tear debris (p = 0.0052), papillae 
(p = 0.0092), and follicles (p = 0.0046) compared to baseline. The Voltaren Ophthalmic-treated eyes 
showed significant decreases in chemosis (p = 0,0113), conjunctival injection (p = 0.0268), tear debris (p 
= 0.0373), papillae (p = 0.0068), and follicles (p = 0.0039). Subjectively patients found more overall 
satisfaction with Voltaren Ophthalmic than with Acular (p = 0.0010). Results of this study show that both 
Acular and Voltaren Ophthalmic are effective in reducing the signs of ocular surface inflammations. 
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Abstract 
Thirty patients with various ocular surface inflammations were 
enrolled in a double-masked study comparing ketorolac 
tromethamine 0.5% (Acular) and diclofenac sodium 0.1% (Voltaren 
Ophthalmic). At the initial visit, baseline measurements of various 
inflammatory signs were taken. The patients were instructed to use 
Acular in one eye and Voltaren Ophthalmic in the other eye four 
times a day for a period of seven days. After this seven day 
treatment period, the patients completed a questionnaire and were 
evaluated for signs of inflammation. At this time, the drops were 
reversed for each eye. Once again the patients were instructed to 
use the drops four times daily for seven days. After this second 
week of treatment the patients were reevaluated for signs and 
symptoms of inflammation. Quantification of signs and symptoms 
occurred at the one week and two week evaluations. After two 
weeks the Acular-treated eyes showed significant decreases in 
conjunctival injection (p = 0.0192), tear debris (p = 0.0052), papillae 
(p = 0.0092), and follicles (p = 0.0046) compared to baseline. The 
Voltaren Ophthalmic-treated eyes showed significant decreases in 
chemosis (p = 0,0113), conjunctival injection (p = 0.0268), tear debris 
(p = 0.0373), papillae (p = 0.0068), and follicles (p = 0.0039). 
Subjectively patients found more overall satisfaction with Voltaren 
Ophthalmic than with Acular (p = 0.0010). Results of this study show 
that both Acular and Voltaren Ophthalmic are effective in reducing 
the signs of ocular surface inflammations. 
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Introduction 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, 
anti-pyretic, and anti-inflammatory activities. The major mechanism 
of action of NSAIDs is believed to be their ability to inhibit the cyclo-
oxygenase pathway and therefore inhibit prostaglandin synthesis. 
Prostaglandins are mediators of inflammation which are believed to 
have the following ocular effects: elevation of intraocular pressure, 
dilation of ocular blood vessels, and pupillary miosis. Prostaglandins 
have been isolated from the ocular tissue and aqueous of inflamed 
eyes.l 
Topical NSAIDs available for ophthalmic use include ketorolac 
tromethamine 0.5% (Acular) and diclofenac sodium 0.1% (Voltaren 
Ophthalmic). The Food and Drug Administration (FDA) has approved 
the use of Acular for the treatment of itching associated with 
seasonal allergic conjunctivitis. Acular is a member of the pyrrolo-
pyrolle group of NSAIDs. The typical dosage regimen for Acular is 
one drop four times a day. Acular's efficacy has not been established 
beyond one week of treatment. The FDA has approved the use of 
Voltaren Ophthalmic for the treatment of postoperative inflammation 
following cataract extraction. Voltaren Ophthalmic is one of a series 
of phenylacetic acids. The typical dosage regimen for Voltaren 
Ophthalmic is one drop four times a day beginning 24 hours after 
cataract surgery and continuing for two weeks after the surgery. 
Other applications for both Acular and Voltaren Ophthalmic 
have been suggested. Studies have shown Acular to be an effective 
treatment in decreasing the signs and symptoms of seasonal allergic 
contact lenses. This study was approved by the Institutional Review 
Board and all patients were required to sign an informed consent 
document prior to participation in the study. 
A file was developed for each study patient which contained 
the informed consent document, patient instructions for use of the 
drops, intern instructions of the study protocol, two subjective 
questionnaires (one week and two week follow-up), three objective 
recording forms (baseline, one week and two week follow-up), 
grading scales for inflammatory signs, and the masked bottles of 
NSAIDs. Both NSAID bottles were covered with white labels and 
marked with either "R" for right eye or "L" for left eye. 
Baseline measurements of lid edema, chemosis, conjunctival 
injection, tear debris, papillae, follicles, fluorescein staining, rose 
bengal staining, cells, and flare were taken on all patients using slit-
lamp biomicroscopy prior to entrance into the study. Noted signs of 
inflammation were rated as follows: 0 = none, 1 = trace, 2 = mild, 3 = 
moderate, and 4 =marked. Intraocular pressure (lOP) was measured 
on all patients using Goldmann applanation tonometry. 
Patients selected for the study were then randomly assigned 
the use of Acular on one eye and Voltaren Ophthalmic on the other 
eye. Patients were asked to administer one drop of the assigned 
agents to each eye four times daily for a period of seven days. After 
the completion of seven days of therapy, all objective measurements 
were retaken, qualified, quantified, and documented for the purpose 
of comparing initial findings to those observed after one week of 
treatment. At this time patients were also asked to fill out a 
subjective questionnaire which included the following items for each 
of the treated eyes: itching of eyes immediately before using drops, 
itching of eyes one minute after using drops, pain immediately 
before using drops, pain one minute after using drops, stinging 
caused by drops, burning caused by drops, excessive tearing, 
photophobia, unusual discharge from eyes, halos in vision, excessive 
blinking, variable vision, and overall satisfaction with the eyedrops. 
A rating scale of 0 to 4 was used to quantify the subjective 
impressions with 0 = none, 1 = rarely occurs, 2 = intermittently 
occurs, 3 = almost always occurs, and 4 = always occurs. At the 
conclusion of the first reexamination, the patients were instructed to 
reverse the two eyedrops. The drop that had previously been used 
to treat the right eye was switched to be used on the left eye, and 
vice versa. The patients were again told to use each of the drops 
four times daily for a period of seven days. At the conclusion of this 
seven day treatment period, slit-lamp biomicroscopy was repeated 
with findings rated using the standard rating scale previously 
mentioned. Once again patients were asked to complete a subjective 
questionnaire comparing symptoms experienced for each of the 
treated eyes. Items included were identical to those of the first 
questionnaire administered. 
Data gathered from the objective and subjective rating scales 
were analyzed separately using the Wilcoxon signed-rank test with a 
significance level of p <0.05. The one week findings in the Acular-
treated eye were compared to the initial findings of that same eye; 
the one week findings in the Voltaren Ophthalmic-treated eye were 
compared to the initial findings of that same eye. Also compared 
after one week were subjective impressions of Acular versus 
Voltaren Ophthalmic. After the second week of treatment, findings 
from the eye that was being treated with Acular were compared to 
the initial findings from that same eye; findings from the eye that 
was being treated with Voltaren Ophthalmic were compared to the 
initial findings from that same eye. Also compared after the second 
week were subjective impressions of Acular versus Voltaren 
Ophthalmic. 
Results 
There were 30 patients with ocular surface inflammation 
enrolled in this study. After one week of treatment, 29 patients 
were allowed to continue in the study (one patient was discontinued 
due to an allergic reaction). After the second week, 26 patients were 
evaluated (three patients failed to return for their second week 
evaluations). An additional eight subjects with no signs or symptoms 
of ocular surface inflammation were used as a control group. 
After one week of treatment, Acular-treated eyes had a 
significant decrease in the amount of rose bengal staining observed 
(p = 0.0423). The Voltaren Ophthalmic-treated eyes had a significant 
decrease in tear debris (p = 0.0052) and follicles (p = 0.0330). No 
significant decrease or increase was noted in the other objective 
measurements (table 1). One patient was discontinued from the 
study at this point due to an allergic reaction to the Voltaren 
Ophthalmic. This patient experienced an increase in chemosis, 
conjunctival injection, papillae, fluorescein staining, and rose bengal 
staining. 
Subjective impressions after one week of treatment showed 
more stinging (p = 0.0192) and excessive tearing (p = 0.0277) with 
the use of Acular than with Voltaren Ophthalmic. No statistical 
significance was noted in any of the other subjectively rated items 
(table 2). 
After the second week of treatment, the Acular-treated eyes 
showed a significant decrease in conjunctival injection (p = 0.0192), 
tear debris (p = 0.0052), papillae (p = 0.0092), and follicles (p = 
0.0046) compared to the initial findings of the same eye. The 
Voltaren Ophthalmic-treated eyes showed a significant decrease in 
chemosis (p = 0.0113), conjunctival injection (p = 0.0268), tear debris 
(p = 0.0373), papillae (p = 0.0068), and follicles (p = 0.0039) 
compared to the initial findings of the same eye. No statistical 
significance was noted in any of the other objective measurements 
(table 1). 
Subjective impressions after the second week showed more 
itch immediately before using the drops in the Acular-treated eye as 
compared to the Voltaren Ophthalmic-treated eye (p = 0.0277). Also 
noted was more burning (p = 0.0121) and excessive tearing (p = 
0.0431) in the eyes treated with Acular as compared to those treated 
with Voltaren Ophthalmic. Subjectively more overall satisfaction was 
found with Voltaren Ophthalmic than with Acular (p = 0.0010) at the 
conclusion of the second week (table 2). 
No statistical significance was noted in any of the objective 
measurements or subjective impressions for the control group. 
Discussion 
This study suggests that both Acular and Voltaren Ophthalmic 
are effective in reducing ocular surface inflammation and that both 
signs and symptoms are reduced, irrespective of the inflammatory 
"trigger". Several sterile inflammations were treated, and many 
were relieved by NSAID treatment. 
After one week of treatment with Acular the only significant 
finding was a decrease in rose bengal staining. After the second 
week of treatment, the Acular-treated eyes showed significant 
decreases in conjunctival injection, tear debris, papillae, and follicles 
compared to baseline. There was also a decrease in chemosis that 
approached significance (p = 0.0630). All of these signs are 
consistent with those found in seasonal allergic conjunctivitis for 
which Acular is indicated. 
Following one week of treatment with Voltaren Ophthalmic, 
significant decreases were noted in tear debris and follicles. At the 
conclusion of the second week, the Voltaren Ophthalmic-treated eyes 
showed significant decreases in chemosis, conjunctival injection, tear 
debris, papillae, and follicles. 
Subjectively after one week of treatment, significantly more 
stinging and tearing were noted with Acular than with Voltaren 
Ophthalmic. At the conclusion of the first week of treatment, there 
was no statistical significance noted in the level of overall satisfaction 
between the two treatments. After the second week of treatment, 
patients noted significantly more itching in the Acular-treated eye 
than in the Voltaren Ophthalmic-treated eye immediately before 
using the drops. Once again with the use of Acular there was 
significantly more burning and tearing noted than with Voltaren 
Ophthalmic. At this point, subjectively, there was also significantly 
more overall satisfaction with Voltaren Ophthalmic than with Acular. 
Our findings suggest that both Acular and Voltaren Ophthalmic 
were effective in reducing the signs and symptoms of ocular surface 
inflammation although Voltaren Ophthalmic was significantly 
preferred by the patients. 
Other studies have found decreases in ocular itching, 
conjunctival inflammation and injection, discharge/tearing, and 
foreign body sensation after one week of treatment with Acular,2,3 
Voltaren Ophthalmic has previously been shown to significantly 
reduce conjunctival injection, ciliary flush, and overall inflammatory 
response.s 
Previous studies have found burning and stinging upon 
instillation to be the most common adverse effect noted with the use 
of Acular.2,3 A transient burning sensation upon instillation has also 
been noted previously with the use of Voltaren Ophthalmic. 8 
Our findings may differ from those of other studies due to the 
fact that we were treating various ocular surface inflammations 
rather than strictly seasonal allergic conjunctivitis or postoperative 
inflammation. 
Throughout the entire study no serious adverse reactions 
occurred with the use of Acular. One patient did experience an 
allergic reaction to Voltaren Ophthalmic. This patient was found to 
have an increase in lid edema, chemosis, conjunctival injection, 
papillae, follicles, fluorescein staining, and rose bengal staining in the 
Voltaren Ophthalmic-treated eye. Upon discovery of the allergic 
reaction, the patient was withdrawn from the study and instructed to 
immediately discontinue use of Voltaren Ophthalmic. A follow-up 
appointment showed a decrease in allergic signs and symptoms 
within 24 hours after discontinuation of the Voltaren Ophthalmic. 
Caution should be used when prescribing NSAIDs due to other 
adverse effects which have been noted including photophobia, gastric 
sensitivity, and increased bleeding time.9 
Neither Acular nor Voltaren Ophthalmic was found to have a 
significant effect on lOP when used in the treatment of ocular surface 
inflammations. Previous studies have also found no significant 
difference in the level of intraocular pressure when using Voltaren 
OphthalmicS,S,lO or Acular4 for the treatment of inflammation 
following cataract extraction. Both Acular4 and Voltaren 
Ophthalmicll,l2 have been found to be as effective as steroids in 
treating postoperative inflammation after cataract surgery. An 
advantage of treating such ocular inflammation with these NSAlDs is 
the fact that they have not been shown to cause the increase in lOP 
which most steroids are known for. 
Conclusion 
Although Acular is only indicated for the treatment of allergic 
conjunctivitis and Voltaren Ophthalmic for postoperative 
inflammation following cataract extraction, this study suggests that 
both of these NSAlDs are effective in the treatment of various ocular 
surface inflammations. This conclusion is supported by others who 
have also suggested that these NSAIDs may be useful in a variety of 
inflammatory ocular conditions.8,13 Further investigation into this 
area would prove beneficial to those patients who suffer from 
various forms of ocular inflammation and to the field of optometry. 
Table 1: p-values 
comparison at 1 comparison at 1 comparison at 2 comparison at 2 
week- Acular to week- Voltaren weeks- Acular weeks- Voltaren 
i ni ti a! to initial to initial to initial 
lid edema 0.7532 0.7532 0.1422 0.1422 
chemosis 0.0858 0.0972 0.0630 0.0113 
conj. injection 0.2787 0.1307 0.0192 0.0268 
corneal edema 0.1797 0.1797 0.1797 0.1797 
tear debris 0.0535 0.0052 0.0052 0.0373 
cells 0.0000 0.0000 0.0000 0.0000 
flare 0.3173 0.3173 0.3173 0.3173 
papillae 0.1579 0.1166 0.0092 0.0068 
follicles 0.0910 0.0330 0.0046 0.0039 
NaFI staining 0.1097 0.2026 0.5303 0.7213 
rose beng. stain 0.0423 0.1282 0.2936 0.1235 
lOP 0.6101 0.7764 0.7299 0.4074 
All of the signs listed above, with the exception of cells and lOP, showed a 
decrease following one and two weeks of treatment. 
Table 2: p-values 
comparison at 1 week- comparison at 2 weeks-
Acular to Voltaren Acular to Voltaren 
Ophthalmic Ophthalmic 
itching immed. before drops 0.5930 A 0.0277 v 
itching 1 min. after drops 0.9165 A 0.0759 v 
pain immed. before drops 0.1797 A 0.3173 v 
pain 1 min after drops 0.4227 v 0.6858 v 
stinging caused by drops 0.0192 v 0.0692 v 
burning caused by drops 0.0995 v 0.0121 v 
excessive tearing 0.0277 v 0.0431 v 
photophobia 0.3173 A 0.3173 v 
unusual discharge 0.3173 A 1.0000 
halos in vision 0.0000 0.3173 A 
excessive blinking 0.0000 0.1797 v 
variable vision 1.0000 0.1797 v 
overall satisfaction 0.0843 v 0.0010 v 
A= Acular 
V = Voltaren Ophthalmic 
These symbols within the table denote that drop which produced the fewest 
symptoms, except for overall satisfaction where the symbol denotes that drop 
which produced the greatest satisfaction. 
Table 3 
week 1 week 2 
lid edema A=V A=V 
chemosis A v 
conj. injection v A 
corneal edema A=V A=V 
tear debris v A 
cells none reported none reported 
flare A=V A=V 
papillae v v 
follicles v v 
NaFl staining A A 
rose beng. stain A v 
A= Acular 
V = Voltaren Ophthalmic 
The symbols in the chart denote that drop which had the greatest effect on 
reducing the given signs of inflammation. 
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